Compugen Announces Board of Directors Appointment

Compugen announced the appointment of Eran Perry to its board of directors, effective July 1, 2019. In addition, the Company announced that Yair Aharonowitz, Ph.D. and Arie Ovadia, Ph.D. will retire from its board of directors and will not be brought for re-election at the next annual general meeting.

"Eran is an accomplished business leader with over 20 years of experience in the healthcare industry as well as general management, strategy and finance. I am confident that his diverse experience will add depth to our board and greatly contribute to the support and guidance we provide the management team," said Paul Sekhri, Chairman of the Board. "I would also like to personally thank Yair and Arie, who will end their tenure as directors in the coming months, for their contributions to Compugen during their many years as board members."

"I am impressed by the progress Compugen has made in recent years, developing cutting edge computational discovery capabilities leading to a differentiated immuno-oncology pipeline," said Perry. "I am delighted to join the Company's board and look forward to working with Paul, the other board members and the executive management team in achieving the Company's long-term strategic objectives and enhancing shareholder value."

Perry brings to Compugen over 20 years of diverse experience across various segments of the healthcare industry as an entrepreneur and venture capital investor as well as in general management and strategy. In 2018, Perry co-founded MII Fund & Labs, a dermatology-focused venture capital fund where he also serves as Managing Director and Chairman of the Investment Committee. Since 2017, Perry has been a co-founder and active board member of ICD Pharma, a developer of cannabis-based pharmaceuticals. Perry is also the co-founder and board member of several pharmaceutical companies including Musli Thyropeutics, Seanergy Dermatology, and Follicle Pharma. From 2006 to 2016, he served as Managing Director and Partner of Israel Healthcare Ventures (IHCV), and represented IHCV in numerous portfolio companies. Prior to IHCV, Perry was a consultant in McKinsey & Company, serving clients worldwide in the pharmaceutical industry, among others. Prior to that, he was a member of the Global Marketing group at Novartis Oncology. Before moving to the private sector, Mr. Perry served in the Israeli Ministry of Justice. Perry holds an MBA from Columbia University, and an LL.B. in Law and a B.Sc. in Mathematics and Computer Science, both from Tel Aviv University.

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com